List of Excipients in Branded Drug SOTYKTU

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	SOTYKTU	deucravacitinib	0003-0895	ANHYDROUS LACTOSE	2033-11-07
ER Squibb & Sons LLC	SOTYKTU	deucravacitinib	0003-0895	CELLULOSE, MICROCRYSTALLINE	2033-11-07
ER Squibb & Sons LLC	SOTYKTU	deucravacitinib	0003-0895	CROSCARMELLOSE SODIUM	2033-11-07
ER Squibb & Sons LLC	SOTYKTU	deucravacitinib	0003-0895	FERRIC OXIDE RED	2033-11-07

Last updated: August 4, 2026

ecutive summary: Sotyktu is a once-daily, immediate-release 6 mg deucravacitinib tablet with a relatively simple excipient system: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a film coat. The strongest commercial opportunities are in excipient supply, low-dose direct-compression manufacturing, lactose-free reformulation, regional generic development, and lifecycle products such as pediatric or alternative oral dosage forms. Because deucravacitinib is a small molecule, biosimilar competition is irrelevant; the main risks are ANDA Paragraph IV challenges, formulation patents, process patents, and regulatory exclusivity.

Sotyktu Excipient Strategy, Formulation Patents, Generic Risk, and Commercial Opportunities

What is Sotyktu and how is it formulated?

Sotyktu is the U.S. brand name for deucravacitinib, an oral, selective tyrosine kinase 2, or TYK2, inhibitor marketed by Bristol Myers Squibb. The FDA approved Sotyktu on September 9, 2022, for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1].

The marketed product is an immediate-release, film-coated tablet administered once daily at a 6 mg dose. Food does not materially affect administration requirements, and the label does not require dosing with meals [1].

Sotyktu inactive ingredients

Formulation component	Function	Commercial relevance
Lactose monohydrate	Diluent and tablet filler	Cost-effective, established excipient; creates lactose-intolerance and label-positioning considerations
Microcrystalline cellulose	Filler and dry-binder	Supports direct compression and tablet mechanical strength
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and immediate release
Magnesium stearate	Lubricant	Controls die ejection and reduces manufacturing friction
Hypromellose	Film-forming polymer	Provides tablet coating and protection
Titanium dioxide	Opacifier and colorant	Supports appearance and light protection
Polyethylene glycol	Plasticizer in film coating	Improves coating flexibility
Iron oxide red	Colorant	Supports product identification and brand appearance

The excipient list is reported in the FDA prescribing information [1]. The formulation does not require a controlled-release polymer, lipid vehicle, solubilizer, enteric coating, or specialized absorption enhancer. That reduces manufacturing complexity and lowers the technical barrier to producing a bioequivalent immediate-release tablet.

Why does Sotyktu use a conventional immediate-release excipient platform?

The formulation reflects the properties of a potent, orally active small molecule. The 6 mg dose permits a compact tablet, while the direct-compression excipient combination provides standard manufacturability, disintegration, and coating performance.

The strategy has four practical advantages:

1. It minimizes the number of critical formulation variables.
2. It supports high-volume tablet production with conventional equipment.
3. It reduces dependence on specialized delivery technologies.
4. It makes a conventional ANDA pathway commercially plausible for generic manufacturers.

The formulation also limits differentiation based solely on excipient selection. A generic developer can generally seek approval for a compositionally different tablet if it demonstrates pharmaceutical equivalence and bioequivalence. The branded excipient combination therefore has less defensive value than the active-ingredient, method-of-use, manufacturing, or specifically claimed formulation patents.

What excipient strategy is most attractive for Sotyktu generics?

The most commercially attractive generic strategy is a low-cost, immediate-release tablet using excipients with broad regulatory precedent and global availability.

Lactose-based formulation

A lactose-based composition is the closest commercial analogue to the marketed product. It offers:

• Low raw-material cost
• Extensive supplier availability
• Familiar compendial specifications
• Straightforward scale-up
• Low formulation development risk

The principal drawback is that lactose can complicate positioning for patients who avoid lactose or for markets where lactose-free labeling has commercial value.

Lactose-free formulation

A lactose-free generic could replace lactose monohydrate with one or more of the following:

• Mannitol
• Anhydrous dibasic calcium phosphate
• Pregelatinized starch
• Additional microcrystalline cellulose
• Spray-dried polyols
• Coprocessed filler-binder systems

A lactose-free product may create a modest commercial distinction, but it would not automatically obtain regulatory exclusivity. The developer would need to manage tablet weight, hardness, friability, disintegration, dissolution, moisture sensitivity, and blend uniformity.

For a 6 mg tablet, content uniformity is more important than total tablet mass. Low drug loading can increase segregation risk during blending and compression. A formulation using a highly uniform premix, geometric dilution, or ordered mixing may reduce that risk.

Direct-compression formulation

Direct compression is likely the preferred platform because the marketed product uses common tablet excipients and does not require a complex granulation process. The primary development issues are:

• Deucravacitinib distribution at low concentration
• Lubricant sensitivity
• Compression-force effects on dissolution
• Powder flow
• Tablet coating uniformity
• Stability under humidity and light exposure

Wet granulation may be commercially justified if the active ingredient has poor flow or poor content uniformity. It would, however, increase manufacturing cost and process-validation burden.

What formulation patents may protect Sotyktu?

Sotyktu’s highest-value intellectual property is likely associated with deucravacitinib composition of matter, therapeutic use, and manufacturing rather than the publicly disclosed excipient list alone.

Potential formulation claim categories include:

• Specific crystalline or amorphous forms
• Polymorph control
• Salt or solvate forms
• Particle-size distributions
• Dissolution profiles
• Tablet compositions
• Stability-enhancing formulations
• Specific coating systems
• Methods for treating plaque psoriasis using defined dosage regimens
• Combinations with other immunomodulatory agents

A generic composition that substitutes excipients may avoid a narrow formulation claim, but it may still infringe a broader claim covering the active compound, a crystalline form, or a method of treatment.

The commercial value of an excipient patent depends on claim breadth. A claim limited to lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate may be easier to design around than a claim covering a defined dissolution profile or a specific solid form of deucravacitinib.

What is the Orange Book status of Sotyktu?

Sotyktu is an FDA-approved small-molecule drug and is eligible for Orange Book listing. The Orange Book is the central source for approved patents and regulatory exclusivity relevant to ANDA applicants [2].

Key regulatory points are:

Issue	Sotyktu position
FDA pathway	New drug application
Active ingredient	Deucravacitinib
Dosage form	Immediate-release tablet
Strength	6 mg
Approval date	September 9, 2022
Regulatory exclusivity	Five-year new chemical entity exclusivity, subject to statutory timing
Biosimilar pathway	Not applicable
Generic pathway	ANDA under section 505(j)
Paragraph IV risk	Depends on Orange Book-listed patents and applicant certification strategy

Five-year NCE exclusivity generally prevents submission of an ANDA containing a Paragraph IV certification for four years after approval, although the timing rules contain statutory exceptions and do not prevent all other submission activity. The commercial consequence is that generic developers must coordinate patent certification, patent expiry, and potential litigation timing rather than rely on exclusivity alone.

When does Sotyktu lose exclusivity?

Sotyktu has several distinct exclusivity layers:

Regulatory exclusivity

The five-year NCE period is expected to run from the September 2022 approval date, subject to FDA application of the statutory rules. This places the main NCE barrier in the 2027 timeframe [1, 3].

Patent exclusivity

Patent expiry may extend beyond regulatory exclusivity. The relevant date depends on the particular patent, patent-term adjustment, patent-term extension, listed use, and any later-issued patents. The FDA Orange Book and USPTO records control the operative dates [2, 4].

Pediatric exclusivity

If BMS completes qualifying pediatric studies under a written FDA request, six months of pediatric exclusivity could attach to eligible patents and regulatory exclusivities. Pediatric exclusivity is not automatic and depends on FDA acceptance of the submitted studies [3].

Market-entry implication

The most probable generic-entry window is controlled by the later of:

• The end of applicable NCE exclusivity
• Expiration or successful challenge of relevant Orange Book patents
• Resolution of Paragraph IV litigation
• Completion of any settlement-restricted entry date

A generic may enter earlier than patent expiry if it prevails in litigation, obtains a covenant not to sue, licenses the relevant rights, or reaches a settlement permitting an agreed launch date.

Which companies are likely to challenge Sotyktu?

Potential challengers include large generic companies with dermatology or immunology portfolios and manufacturers with strong low-dose oral solid-dose capabilities. Likely candidate profiles include:

• Teva Pharmaceutical Industries
• Sandoz
• Viatris
• Sun Pharmaceutical Industries
• Dr. Reddy’s Laboratories
• Zydus Lifesciences
• Aurobindo Pharma
• Cipla
• Lupin
• Hikma Pharmaceuticals

No company should be treated as an actual Paragraph IV challenger without an FDA filing, litigation complaint, or public company disclosure. The commercial probability of challenge depends on market size, remaining patent life, manufacturing complexity, and expected post-entry price erosion.

What generic launch risks exist for Sotyktu?

Patent litigation risk

A first filer could face a patent-infringement action after a Paragraph IV notice. Under Hatch-Waxman, a timely infringement action can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court action [5].

Low-dose content-uniformity risk

The 6 mg strength is small relative to the tablet mass. Poor blend uniformity can create out-of-specification dosage units even when the overall batch assay is acceptable.

Dissolution risk

A generic may use different excipients, but its dissolution profile must remain comparable to the reference product. Changes in disintegrant level, lubricant concentration, compression force, or granulation method can affect release.

Solid-form risk

If the reference product uses a protected crystalline form, a generic may need to demonstrate that its form is noninfringing or obtain a different form with adequate stability and bioavailability.

Supply-chain risk

The excipients themselves are widely available. The higher supply risk is likely to involve qualified API production, solid-form control, analytical reference standards, and validated commercial-scale manufacturing.

How strong is the Sotyktu patent estate?

The estate should be assessed in layers rather than by patent count alone.

Patent layer	Strategic value	Design-around potential
Deucravacitinib composition of matter	Very high	Very low before expiry
Crystalline form or solid-state claims	High	Moderate, depending on claim scope
Therapeutic method claims	High for labeled use	Moderate to high, depending on indication and label
Tablet formulation claims	Moderate	Often moderate to high
Manufacturing-process claims	Moderate	Moderate, if alternative routes are available
Coating or excipient claims	Low to moderate	Usually high
Combination-treatment claims	Selective	Depends on label and product strategy

A patent estate with multiple independent barriers can delay entry more effectively than a formulation patent standing alone. The strongest generic strategy is typically an early noninfringement or invalidity analysis focused on composition-of-matter and solid-form claims, followed by formulation development that avoids unnecessary overlap.

What commercial opportunities exist in Sotyktu excipients?

Excipient supply

Excipient suppliers can target:

• Direct-compression microcrystalline cellulose
• Low-moisture lactose grades
• High-functionality croscarmellose sodium
• Low-peroxide hypromellose
• Pigment systems for color-matched film coatings
• Coprocessed filler-binders for lactose-free products

The opportunity is more attractive for suppliers that can provide regulatory documentation, particle-size control, low bioburden, elemental-impurity data, and multi-region registration support.

Formulation development services

Contract development and manufacturing organizations can offer:

• Low-dose blend-uniformity optimization
• Reference-product reverse engineering
• Dissolution matching
• Film-coating development
• Solid-form screening
• Scale-up from pilot to commercial tablet presses
• Stability programs under ICH conditions

Alternative dosage forms

Potential lifecycle products include:

• Smaller tablets for patients with swallowing difficulty
• Orally disintegrating tablets
• Pediatric mini-tablets
• Sprinkle formulations
• Oral granules
• Unit-dose sachets

These products would require clinical, bioequivalence, or comparative dissolution strategies appropriate to the dosage form. Their value would be greatest if they address adherence, pediatric use, swallowing limitations, or regional administration preferences.

Combination products

A fixed-dose combination involving deucravacitinib and another psoriasis therapy could reduce pill burden, but it would require clinical justification, dose selection, compatibility data, and regulatory support. Combination development also creates additional patent and safety issues.

How does Sotyktu compare with competing oral psoriasis drugs?

Product	Active ingredient	Administration	Excipient opportunity	Competitive position
Sotyktu	Deucravacitinib	Once-daily oral tablet	Conventional immediate-release platform; lactose-free and pediatric opportunities	Selective TYK2 mechanism
Otezla	Apremilast	Oral tablet	Established generic and formulation competition	Mature oral psoriasis market
Xeljanz	Tofacitinib	Oral tablet	Generic-entry and alternative formulation opportunities	Broader immunology exposure
Rinvoq	Upadacitinib	Extended-release tablet	More complex release technology	Strong oral immunology competitor
Biologic therapies	Various antibodies	Injection or infusion	Parenteral excipient and device opportunities	Higher manufacturing complexity

Sotyktu’s once-daily oral administration and selective TYK2 mechanism support commercial differentiation. Its conventional tablet architecture makes it more accessible to generic manufacturers than an extended-release or device-dependent product.

What geographic opportunities exist for Sotyktu excipients?

The United States is the principal patent and Orange Book market, but excipient and generic opportunities are broader:

• European Union: centralized or national regulatory strategies, with local patent and supplementary protection certificate analysis
• Japan: formulation and local manufacturing opportunities under Japanese PMDA requirements
• China: domestic generic development and excipient localization
• India: API, formulation, and contract manufacturing opportunities
• Latin America: price-sensitive generic markets with varied patent enforcement
• Middle East and Africa: supply partnerships and finished-dose procurement opportunities

A global lactose-free platform may provide greater commercial flexibility than a U.S.-optimized formulation because excipient preferences, labeling expectations, and local manufacturing infrastructure vary by market.

What patent litigation and settlement issues affect Sotyktu?

The key litigation questions are whether an ANDA filer:

1. Makes a Paragraph IV certification against an Orange Book patent.
2. Receives a patent-infringement complaint within the statutory period.
3. Obtains a 30-month stay of approval.
4. Prevails on invalidity or noninfringement.
5. Reaches a settlement with BMS.
6. Receives a licensed or agreed launch date.

A settlement can convert uncertain litigation into a negotiated entry date. It can also restrict the generic’s launch, manufacturing, supply, or authorized-generic arrangements. Any commercial forecast should distinguish a tentative ANDA filing from actual litigation and should not assume that an early filing produces an early launch.

Key Takeaways

• Sotyktu is a 6 mg once-daily immediate-release deucravacitinib tablet.
• The marketed excipient system is conventional and includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, and iron oxide red.
• The strongest generic opportunity is a conventional direct-compression tablet with optimized low-dose content uniformity.
• Lactose-free, orally disintegrating, pediatric, and sprinkle formulations offer the clearest excipient-led differentiation.
• Biosimilar risk does not apply because deucravacitinib is a small molecule.
• NCE exclusivity places the principal regulatory barrier in the 2027 timeframe, while patent expiry and litigation may control actual entry.
• Composition-of-matter and solid-form patents are likely to provide stronger protection than narrow excipient claims.
• Excipient suppliers and CDMOs can compete through high-functionality materials, regulatory support, blend-uniformity solutions, and global manufacturing packages.

FAQs

Can a generic Sotyktu tablet use different excipients?

Yes. An ANDA applicant may use a different inactive-ingredient system if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements.

Is lactose-free Sotyktu commercially viable?

Yes. A lactose-free product could target patients and markets that prefer non-lactose formulations, but it would need to match the reference product’s performance and provide a defensible commercial advantage.

Does Sotyktu require a complex drug-delivery system?

No. The marketed product is an immediate-release film-coated tablet and does not depend on extended-release polymers, lipid delivery, or an absorption-enhancing technology.

Can excipient substitution avoid Sotyktu patent infringement?

It may avoid a narrow formulation claim, but excipient substitution does not by itself avoid patents covering deucravacitinib, a protected solid form, a manufacturing process, or a method of treatment.

What is the most valuable Sotyktu lifecycle opportunity?

A pediatric or swallow-friendly oral dosage form is likely to offer more value than a simple excipient substitution because it can address administration barriers and potentially support a differentiated regulatory and commercial position.

References

1. U.S. Food and Drug Administration. (2022). SOTYKTU (deucravacitinib) tablets, prescribing information. Bristol-Myers Squibb Company.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). Small business assistance: Frequently asked questions on the patent term restoration and non-patent exclusivity provisions. https://www.fda.gov/

4. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources. https://www.uspto.gov/

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application: Submissions and approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/